These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 4005766)
1. Excipients and additives. Shear NH; Dupuis LL; Zimmerman B Can Med Assoc J; 1985 Jul; 133(2):93. PubMed ID: 4005766 [No Abstract] [Full Text] [Related]
2. Inactive ingredients listed in labeling. FDA Drug Bull; 1985 Dec; 15(4):39-40. PubMed ID: 4092906 [No Abstract] [Full Text] [Related]
3. Psychotropic drug labeling: regulatory, pharmaceutical industry, and clinical issues and perspectives. A pharmaceutical industry perspective on drug labeling. Robinson DS Psychopharmacol Bull; 1994; 30(1):23-5. PubMed ID: 7972625 [No Abstract] [Full Text] [Related]
4. Incomplete labeling of pharmaceuticals: a list of "inactive" ingredients. Brown JL N Engl J Med; 1983 Aug; 309(7):439-41. PubMed ID: 6877311 [No Abstract] [Full Text] [Related]
6. Man in plant. Archambault GF Hosp Formul; 1977 Nov; 12(11):826. PubMed ID: 10305391 [No Abstract] [Full Text] [Related]
7. The Food and Drug Administration's regulation of drug labeling, advertising, and promotion: looking back and looking ahead. Hayes TA Clin Pharmacol Ther; 1998 Jun; 63(6):607-16. PubMed ID: 9663174 [No Abstract] [Full Text] [Related]
8. AHI perspectives: flexible drug labeling and its impact on the drug development process. Liability issues. Thomas JW J Am Vet Med Assoc; 1995 Oct; 207(7):899-900; discussion 902-4. PubMed ID: 7559021 [No Abstract] [Full Text] [Related]
9. Relative efficacy. Stetler CJ J Med Assoc Ga; 1972 Sep; 61(9):312-5. PubMed ID: 5080001 [No Abstract] [Full Text] [Related]
11. On the accountability problem of the pharmaceutical industry. Roberts CD Pharmazie; 1973 Jan; 28(1):49-51. PubMed ID: 4714241 [No Abstract] [Full Text] [Related]
12. FDA proposes more stringent pediatric-use labeling of prescription drug products. Clin Pharm; 1993 Jan; 12(1):6. PubMed ID: 8428434 [No Abstract] [Full Text] [Related]
13. Relative efficacy. When the government decides what drugs should be prescribed, is the patient better served? Ohio State Med J; 1972 Aug; 68(8):748-52 passim. PubMed ID: 5077306 [No Abstract] [Full Text] [Related]
14. All may not be meeting the eye. Archambault GF Hosp Formul; 1975 Aug; 10(8):414. PubMed ID: 10237848 [No Abstract] [Full Text] [Related]
15. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate. Dorfman HL; Quinn VM; Brophy EA Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765 [No Abstract] [Full Text] [Related]
16. Remarks by the Commissioner of Food and Drugs. Kessler DA Food Drug Law J; 1995; 50(2):327-34. PubMed ID: 10343001 [No Abstract] [Full Text] [Related]
17. Excipients and additives: hidden hazards in drug products and in product substitution. Napke E; Stevens DG Can Med Assoc J; 1984 Dec; 131(12):1449-52. PubMed ID: 6498699 [TBL] [Abstract][Full Text] [Related]
18. Name, dosage form and strength. Davis NM Hosp Pharm; 1977 Sep; 12(9):400. PubMed ID: 10305448 [No Abstract] [Full Text] [Related]
19. "Safer, but not safe enough". Crombie HD Conn Med; 2006; 70(10):645. PubMed ID: 17190395 [No Abstract] [Full Text] [Related]
20. View from the Nation's Capital. Romansky MA J Clin Psychopharmacol; 1983 Feb; 3(1):47-8. PubMed ID: 6680403 [No Abstract] [Full Text] [Related] [Next] [New Search]